Schizophrenia study finds new biomarker, drug candidate to treat cognitive symptoms

A new Northwestern University study in humans and mice has discovered a novel biomarker of schizophrenia that could also serve as a new drug candidate to treat the cognitive symptoms of the disorder. Schizophrenia affects .5% of the world’s population, including about two million people in the U.S.

That would be an incredible cure and raises the ethical question of how to get schizophrenic people well enough to understand that they need it.
You just do your best and leave them alone otherwise.